TKI Dose Escalation After mRCC Progression Beneficial

2016-10-04T17:16:49+02:00October 4th, 2016|Drug treatments, Homepage Feature, Treatment Options|

Dose escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more